How Biopharma BD&L Teams are Enhancing Decision Support Capabilities
Biopharma business development and licensing (BD&L) executives operate in a unique arena, enjoying a privileged view of future pipeline plans while shouldering the weight of high-stakes, high-visibility decisions.
Biopharma Needs a Health System Strategy to Secure Optimal Market Access
If somebody asked for evidence of how the healthcare landscape is rapidly changing, a primary exhibit would have to be the growing importance of Integrated Delivery Networks (IDNs) and health systems.
Biopharma Must Transform its Payer Launch Playbook
US payers reject 69% of prescriptions during the first year of a new drug’s FDA approval, and these early rejection rates are only nominally improved in the ensuing years.1 Such a high payer rejection rate is stunning on its own, but this doesn’t even reflect the countless instances when healthcare providers, purely out of a learned […]
A better path to payer insights
Last year, a marketer with two decades of big pharma experience joined one of the healthcare industry’s many emerging biotech startups. With a promising new drug in Phase III and venture capital funding well in hand, he embraced this opportunity as his career capstone. The payer launch plan he inherited appeared comprehensive, but the […]
Biopharma leaders prepare to navigate Medicare’s new negotiating power
The importance of the Medicare market to biopharma’s success in the United States cannot be overstated. The Centers for Medicare and Medicaid Services (CMS) reports its enrollment is more than 60 million Americans,1 and its annual Part B and Part D drug spending exceeds $237 billion.2 Given Medicare’s importance to manufacturers, any legislative changes to this government program […]
Will your clinical trials deliver the leverage you need with payers?
Biopharma manufacturers struggle to communicate the clinical value of their medicines to payers for many reasons: payer drug evaluations are conducted in secrecy, promotional messaging to payer P&T committee members is largely prohibited, and rebate negotiations dominate manufacturer-payer engagements. These challenges are further compounded by the payer community’s legions of pharmacist drug evaluators declaring a […]
A better path to payer insights
Biopharma leaders prepare to navigate Medicare’s new negotiating power
Will your clinical trials deliver the leverage you need with payers?
Novel therapies can appear to demonstrate impressive Phase III results, but if payers do not discern sufficient value, they will seek to limit that product’s access to patients.